Literature DB >> 22964373

Quantitative CT analysis of small pulmonary vessels in lymphangioleiomyomatosis.

Katsutoshi Ando1, Kazunori Tobino, Masatoshi Kurihara, Hideyuki Kataoka, Tokuhide Doi, Yoshito Hoshika, Kazuhisa Takahashi, Kuniaki Seyama.   

Abstract

BACKGROUNDS: Lymphangioleiomyomatosis (LAM) is a destructive lung disease that share clinical, physiologic, and radiologic features with chronic obstructive pulmonary disease (COPD). This study aims to identify those features that are unique to LAM by using quantitative CT analysis.
METHODS: We measured total cross-sectional areas of small pulmonary vessels (CSA) less than 5mm(2) and 5-10mm(2) and calculated percentages of those lung areas (%CSA), respectively, in 50 LAM and 42 COPD patients. The extent of cystic destruction (LAA%) and mean parenchymal CT value were also calculated and correlated with pulmonary function.
RESULTS: The diffusing capacity for carbon monoxide/alveolar volume (DL(CO)/VA %predicted) was similar for both groups (LAM, 44.4 ± 19.8% vs. COPD, 45.7 ± 16.0%, p=0.763), but less tissue damage occurred in LAM than COPD (LAA% 21.7 ± 16.3% vs. 29.3 ± 17.0; p<0.05). Pulmonary function correlated negatively with LAA% (p<0.001) in both groups, yet the correlation with %CSA was significant only in COPD (p<0.001). When the same analysis was conducted in two groups with equal levels of LAA% and DL(CO)/VA %predicted, %CSA and mean parenchymal CT value were still greater for LAM than COPD (p<0.05).
CONCLUSIONS: Quantitative CT analysis revealing a correlation between cystic destruction and CSA in COPD but not LAM indicates that this approach successfully reflects different mechanisms governing the two pathologic courses. Such determinations of small pulmonary vessel density may serve to differentiate LAM from COPD even in patients with severe lung destruction.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22964373     DOI: 10.1016/j.ejrad.2012.05.033

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Lymphangioleiomyomatosis: current and future.

Authors:  Maria Mavroudi; Paul Zarogoulidis; Nikolaos Katsikogiannis; Kosmas Tsakiridis; Haidong Huang; Antonios Sakkas; Anastasios Kallianos; Aggeliki Rapti; Eirini Sarika; Ilias Karapantzos; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

2.  Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.

Authors:  Katsutoshi Ando; Hiroshi Kuraishi; Tetsutaro Nagaoka; Takeo Tsutsumi; Yoshito Hoshika; Toru Kimura; Hiroki Ienaga; Yoshiteru Morio; Kazuhisa Takahashi
Journal:  Lung       Date:  2015-10-09       Impact factor: 2.584

3.  Relationship between quantitative CT metrics and pulmonary function in combined pulmonary fibrosis and emphysema.

Authors:  Katsutoshi Ando; Mitsuaki Sekiya; Kazunori Tobino; Kazuhisa Takahashi
Journal:  Lung       Date:  2013-10-02       Impact factor: 2.584

4.  Pulmonary lymphangioleimyomatosis and systemic lupus erythematosus in a menopausal woman.

Authors:  Hong Hong; Ruiheng Yang; Xiuzhen Li; Mengjun Wang; Zhongchao Ma
Journal:  BMC Nephrol       Date:  2018-04-18       Impact factor: 2.388

5.  Quantitative assessment of pulmonary function in lymphangioleiomyomatosis patients using high-resolution computed tomography and pulmonary function tests.

Authors:  Zhiwen Ni; Thomas S C Ng; Jie Liu; Suidan Huang; Xiaoling Li; Xiaoyin Xu; Huai Chen
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

6.  Lung Transplantation for Lymphangioleiomyomatosis in Japan.

Authors:  Katsutoshi Ando; Yoshinori Okada; Miki Akiba; Takashi Kondo; Tomohiro Kawamura; Meinoshin Okumura; Fengshi Chen; Hiroshi Date; Takeshi Shiraishi; Akinori Iwasaki; Naoya Yamasaki; Takeshi Nagayasu; Masayuki Chida; Yoshikazu Inoue; Toyohiro Hirai; Kuniaki Seyama; Michiaki Mishima
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.